Vycor Medical, Inc.
VYCO
$0.07
$0.00-0.29%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 11.65% | 17.25% | 31.85% | 30.79% | 17.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.65% | 17.25% | 31.85% | 30.79% | 17.56% |
| Cost of Revenue | 48.31% | 81.24% | 84.50% | 73.04% | 37.39% |
| Gross Profit | 6.53% | 9.74% | 25.69% | 25.68% | 15.22% |
| SG&A Expenses | 0.67% | 7.44% | 10.90% | 15.81% | 16.49% |
| Depreciation & Amortization | -1.51% | 0.00% | 0.85% | 1.71% | 2.58% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.40% | 14.45% | 18.05% | 21.71% | 18.21% |
| Operating Income | 845.97% | 472.53% | 196.97% | 127.14% | -376.92% |
| Income Before Tax | 89.91% | 34.39% | 92.38% | 56.43% | -13.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 89.91% | 34.39% | 92.38% | 56.43% | -13.64% |
| Earnings from Discontinued Operations | -2,100.00% | -1,000.00% | 37.50% | 47.22% | 98.33% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 88.01% | 32.31% | 91.47% | 56.25% | -7.37% |
| EBIT | 845.97% | 472.53% | 196.97% | 127.14% | -376.92% |
| EBITDA | 198.65% | 77.19% | 605.59% | 505.16% | -10.96% |
| EPS Basic | 22.73% | 9.16% | 35.44% | 22.29% | 0.75% |
| Normalized Basic EPS | 90.48% | 35.00% | 94.44% | 60.00% | -10.53% |
| EPS Diluted | 21.97% | 8.40% | 34.81% | 21.66% | 2.94% |
| Normalized Diluted EPS | 85.71% | 30.00% | 91.67% | 57.14% | 0.00% |
| Average Basic Shares Outstanding | 0.91% | 1.49% | 2.07% | 1.92% | 1.35% |
| Average Diluted Shares Outstanding | 4.92% | 5.51% | 6.12% | 5.98% | -2.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |